EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase II)Multizentrische StudieVergleichsstudieOpen Access · CC BY 4.0

Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization

Phillip Scheinberg, Matt R Khoshnevis, Philip A Robinson, Alfredo Guerreros iD, Victor A H Sato, Benedito A L Fonseca iD, Hans W Prozesky iD, José Omar Chacón Romero, Laura Fogliatto, Barry R Meisenberg iD, David J Park, Ashok Gupta und 4 weitere

ImmunoHorizons · 2025

DOI: 10.1093/immhor/vlaf023 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ImmunoHorizons, 2025. Verfasst von Phillip Scheinberg und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil. Hauptthemen laut MEDLINE: Pyrazines, Benzamides, COVID-19 Drug Treatment, Protein Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca, Gaithersburg, MD, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The efficacy and safety of acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, was evaluated in 2 phase 2 studies in hospitalized patients with coronavirus disease 2019 (COVID-19) who received acalabrutinib + best supportive care (BSC) versus BSC alone (Clinicaltrials.gov: NCT04380688 and NCT04346199). The primary endpoint was the percentage of patients alive and free of respiratory failure on day 14 (rest of the world [RoW] study) and day 28 (US study). In the RoW study, 177 patients were randomized (acalabrutinib + BSC: n = 89; BSC: n = 88); in the US study, 62 patients were randomized (acalabrutinib + BSC: n = 31; BSC: n = 31). The percentage of patients who met the primary endpoint was similar in both studies (RoW study: acalabrutinib + BSC: 83.1%, BSC: 90.9%; US study: acalabrutinib + BSC: 80.6%, BSC: 83.9%). No new safety concerns were reported. Overall, no significant clinical benefit of adding acalabrutinib to BSC in patients hospitalized with COVID-19 was observed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PyrazinesBenzamidesCOVID-19 Drug TreatmentProtein Kinase InhibitorsHumansMaleFemaleMiddle AgedCOVID-19HospitalizationAgedSARS-CoV-2AdultTreatment OutcomeAgammaglobulinaemia Tyrosine KinaseAged, 80 and over

Stichwörter der Autor:innen

COVID-19acalabrutinibbest supportive carebruton tyrosine kinase inhibitorhospitalized patients

Substanzen

acalabrutinibPyrazinesBenzamidesAgammaglobulinaemia Tyrosine KinaseProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Hematology, Hospital A Beneficência Portuguesa, São Paulo, Brazil.
  • Center for Critical Care, Houston Methodist Hospital, Houston, TX, United States.
  • Infection Prevention and Hospital Epidemiology, Hoag Memorial Hospital Presbyterian, Newport Beach, CA, United States.
  • Department of Medicine, Clinica Internacional, Lima, Peru.
  • International Research Center, Hospital Alemao Oswaldo Cruz, São Paulo, Brazil.
  • Hospital das Clínicas da Faculdade de Medicina de Ribeirão Preto da Universidade de São Paulo (FMRP), São Paulo, Brazil.

ORCID-Profile: Alfredo Guerreros, Benedito A L Fonseca, Hans W Prozesky, Barry R Meisenberg, Veerendra Munugalavadla

Förderung

  • AstraZeneca, Gaithersburg, MD, USA

Zitieren

APA

Scheinberg, P., Khoshnevis, M. R., Robinson, P. A., Guerreros, A., Sato, V. A. H., Fonseca, B. A. L., Prozesky, H. W., Romero, J. O. C., Fogliatto, L., Meisenberg, B. R., Park, D. J., Gupta, A., Patel, P., Townsley, D. M., Zheng, L., & Munugalavadla, V. (2025). Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization. ImmunoHorizons. https://doi.org/10.1093/immhor/vlaf023

Vancouver

Scheinberg P, Khoshnevis MR, Robinson PA, Guerreros A, Sato VAH, Fonseca BAL, et al. Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization. ImmunoHorizons. 2025. doi:10.1093/immhor/vlaf023

BibTeX
@article{Scheinberg2025,
  author = {Scheinberg, Phillip and Khoshnevis, Matt R and Robinson, Philip A and Guerreros, Alfredo and Sato, Victor A H and Fonseca, Benedito A L and Prozesky, Hans W and Romero, José Omar Chacón and Fogliatto, Laura and Meisenberg, Barry R and Park, David J and Gupta, Ashok and Patel, Priti and Townsley, Danielle M and Zheng, Lianqing and Munugalavadla, Veerendra},
  title = {Efficacy and safety of acalabrutinib with best supportive care versus best supportive care in patients with COVID-19 requiring hospitalization},
  journal = {ImmunoHorizons},
  year = {2025},
  doi = {10.1093/immhor/vlaf023}
}
Kostenlos starten →